Register for our EIS fund today

A passion for

innovation

We are constantly innovating our people, project management and technology models leading to outstanding results for our collaborators. The world’s first app based technology platform Chemistry in the CloudTM enables us to work together to make faster decisions. Our deep understanding that an early and intensive evaluation of target molecules based on real insight into the science will lead to faster downstream execution. The result is a higher throughput of successful drug-like compounds.

Project initiation

A keen understanding of collaborators priorities and a fast start are the two essential features for discovery projects at o2h.

Project initiation process starts with business development, where our managers ensure that scientific and other project priorities are identified with each collaborators and communicated to the project leader. At the first collaborators meeting with the team, a questionnaire is populated with details of compound priorities, delivery scheduling, communication format and delivery, access to dedicated intranet project site etc. These details form the crux of all collaborators interactions at o2h.

All collaborators initiation data is coupled with internal processes involving project team allocation and emailing of the project team introduction form and are together a part of the fast start metrics. This metric is collected and evaluated monthly at o2h to monitor and ensure right start of each project.

Feedback

Continuous improvement is the central ethos of all work carried out at o2h and this has been a valuable part of our growth story, where client feedback has played a central role. Client feedback is also used internally as a component to employee bonus.

A detailed client feedback form is sent at the end of each project or at the end of the year (for longer projects). Responses from this feedback form are analysed against project priorities set in the project initiation form and this analysis is discussed with the client to ensure client satisfaction. For longer term projects, this is also an opportunity for all stake-holders to re-visit their priorities and ensure that effective research goals are set/re-defined.

Our communications are tailored to highlight any potential challenges during the project and to take immediate corrective action. In cases where any problems are identified in the client feedback form, the analysis performed with the team ensures that we learn from this experience, take corrective action and avoid miss-steps in future projects. A client feedback form is treated as a part of the operational process rather than a stand-alone exercise to continuously learn, improve and grow the strengths of our employees and o2h.

Testimonial

o2h has grown its business from collaborator references, some of which we would like to share with you. Please get in touch if you would like to contact some of our collaborators to explore working with us on your drug discovery projects.

o2h have supported's drug discovery activities for the past 10 years! As part of our ongoing joint collaborative agreement, …. was pleased to award o2h with their first milestone payment.

UK Biotech

The …..-o2h collaboration is progressing in a good direction, with recent advances in one of our series pushing potencies 100-fold since initiated chemistry in August 2015. We are looking forward to further develop the collaboration between our teams!

Swedish Biotech

o2h have been instrumental in spinning out …. from both investment to discovery activities which are essential for virtual biotech companies. Their business model of investment and risk sharing is innovative and they have been be very helpful and responsive to our needs as a small start-up company

UK Biotech

o2h have been quick to respond and support our discovery efforts with whatever is required to support the company. They are flexible and skills span beyond synthesis. A highly valued collaborator.

Israeli Biotech

Happy to be working with o2h, now that I'm sailing under a new flag. Thanks to the energy and effort of the team at o2h, …… is moving very rapidly to build an exciting new technology. Many thanks to all!

US Biotech

o2h supported our discovery efforts in a highly professional way and delivered quickly to a high purity and were also very good value for money!

Israeli Biotech

Discovery News

22 Jun 2018

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage. PhoreMost has built a pipeline of novel targets and early drug discovery programmes using its next-generation “SITESEEKER®” phenotypic screening platform. The collaboration will see o2h deploy its expertise in medicinal chemistry to help progress PhoreMost’s portfolio rapidly through the hit-to-lead and lead-optimisation stages of drug discovery. Dr Chris Torrance CEO of PhoreMost, said: “Since its inception, PhoreMost’s model has been to forge a new approach to drug discovery, working collaboratively with partners in order to progress new medicines. The alliance with o2h truly reflects this, and represents an important step in our mission to bring a greater diversity of therapies to patients, more quickly and at affordable prices.”  We have been impressed by the ability of PhoreMost’s SITESEEKER platform to systematically identify first-in-class drug targets in areas of high unmet need, and are excited to be applying our highly complementary capabilities to develop these potentially high value programs,” said Sunil Shah, CEO of o2h discovery: “Our shared vision of working collaboratively is also a testament to the strength of the Cambridge UK Biotech cluster for discovery and progressing the next generation of therapeutics.” PhoreMost recently announced the completion of an £11m ($15m) Series-A investment round. The investment will be used to expand operations on the Babraham Research Campus and progress several novel drug targets from its next-generation “SITESEEKER” phenotypic screening platform into first-in-class drug discovery programmes. Press Link - Phoremost and o2h Discovery

18 Apr 2018

Curza Global, LLC and O2H DISCOVERY (O2H) are pleased to announce a multi FTE chemistry collaboration to support Curza as it drives its lead program targeting dram negative through lead optimization and towards the clinic. Curza’s lead program is a new class of broad spectrum antibiotics, focused on ESKAPE pathogens and drug-resistant Gram-negative bacteria. Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome. o2h is pleased to collaborate with industry leader, Curza, to tackle the rapid and global spread of antimicrobial resistance. Working through different pathways Curza hopes to design effective new drugs to tackle gram-negative infections The approach Curza has taken is unique and management is very focused to ensure their drug makes its way to patients quickly. Sunil Shah, CEO of O2h “The rapid and global spread of antimicrobial-resistant organisms in recent years has been unprecedented. Although resistant Gram-positive infections have been concerning to clinicians, the increasing incidence of antibiotic-resistant Gram-negative infections have become the most pressing issue in bacterial resistance.” Ryan Davies, CEO of Curza “We are very happy to be working with O2h on this program. We wanted to make fast progress with this project and O2h’s focus on execution speed is a key reason why we selected them to work on our highest priority project. About O2h: o2h seeds new ideas in science, technology and social enterprise. We work across boundaries and take a collaborative and shared approach to innovation, and therefore we co-invest, co-create and co-execute to bring these ideas to life. o2h discovery is an integrated chemistry and biology services capability for collaborative research and o2h ventures supports early stage life science assets through seed investment. o2h is organized into 6 verticals including discovery, ventures, technology, therapeutics, co-work and community, and is co-located in Ahmedabad, India and in Cambridge UK. Please see www.o2h.com for more details. About Curza: Curza is a Utah-based drug development company focused on developing novel therapeutics to control antibiotic resistant bacteria. With original technology licensed from the University of Utah, Curza is in the early stages of developing two novel classes of antibiotics. Headquartered in Salt Lake City, UT with offices in Cambridge, MA, Curza is privately held and backed by Clarke Capital Partners and other private investors. Please visit www.curza.com for more information.

02 Nov 2017

The quest to positively benefit the lives of patients in the world of drug discovery means finding novel therapeutics for unmet medical needs. The biotech and pharma companies have been increasingly resorting to external innovation to supplement their pipeline of ideas and turbocharge their research-based businesses with enterprising partners with complementary ideas, capabilities and services. It is therefore hardly surprising that the top medicinal chemists working in both large and small companies have multiple partners across different continents and time-zones. To deliver these iterative discovery projects often entails detailed co-ordination of inter-related activities and extensive multi-tasking. Project management is the hub that allows these complex matrices of networks to communicate and for the project to successfully advance. In today’s fast paced and technologically advanced digital world, providing the project manager the right tools to make informed decisions is key to successful delivery. o2h Discovery’s innovative app Chemistry in the Cloud TM builds upon the latest advances in secure cloud-based mobile technology and integrates project management of external drug discovery programs. The app enables communication between the various scientific stakeholders essential to successful project advancement leading to faster decision making. It negates the onerous tasks of weeding out critical information that is required to take a complex decision by extracting the information from large data intensive reports and databases. These crucial decision points are now just a ‘tap/swipe-of-the-finger’ in the Chemistry in the CloudTM app so that they can speedily execute tasks anytime, anywhere. The communication covering a gamut of research activities in relation to process of research now truly happens in 24/7 real-time. o2h announced a worldwide launch and first live demonstration of our revolutionary project management app – Chemistry in the Cloud TM on 10th September 2017 at the 19th RSC/SCI Cambridge medicinal chemistry conference to some of world’s top scientists. The app’s full suite of project management tools is available exclusively to live project collaborators and a lighter version is open for researchers looking for a quote for the synthesis of small molecules. https://www.linkedin.com/in/sunil-shah-4bb225/detail/recent-activity/shares/ Nilesh Dagia (nilesh@o2h.com) is the COO @ o2h Discovery

@o2hventures

December 14th 2018 01:12:11

RT @chategroup_: World Energy Conservation Day is celebrated on 14th December globally to highlight the importance of energy consumption an…

@o2hventures

December 11th 2018 12:12:27

RT @OncologyEvent: Chemists discover an unexpected synergy between two types of cancer drugs!
Visit: https://t.co/O7fvQ3FzUf
#health #can…

@o2hventures

December 11th 2018 11:12:27

RT @aheblog: Our latest #healtheconomics round-up discusses a leading article in PharmacoEconomics on the inclusion of future costs in cost…

@o2hventures

December 11th 2018 08:12:31

RT @JonathanHoltby: Just told my most harrowing Startup Failure story at the Cambridge Startups: Failure event. Broke me at the time - felt…

@o2hventures

December 7th 2018 01:12:04

Speaker and Panelist @sunilshah123, CEO at o2h, also part of Cambridge Angels, attending the Failure meetup in Camb… https://t.co/v6nyVE9L4N

@o2hventures

December 7th 2018 10:12:59

RT @Emmin: Our very own #cambridgeangel Sunil Shah on the panel at The Lab, talking about Cambridge failures #cambridgefailedme https://t.c

@o2hventures

December 7th 2018 10:12:54

RT @markamzprospect: Full house at The Lab celebrating failure! My takeaway celebrate successes no matter how small. Fun and informative ev…

@o2hventures

December 7th 2018 09:12:08

Speaker and Panelist @sunilshah123 CEO @o2hventures attending the Failure meetup @TheLabCambridge #cambridgefailedme https://t.co/LK2tJidJ0A

@o2hventures

December 5th 2018 10:12:04

Make no bones about it, research aboard the Space Station has led to the development of new drugs on Earth that com… https://t.co/M3u3KQMqbE

@o2hventures

December 3rd 2018 02:12:46

o2h cordially invites you to our remarkable event Cambridge Squared held on Tue 11th of Dec aiming to greet and bui… https://t.co/OUlkmbevxI

o2h culture, people & careers

Subscribe to our newsletter